1. Home
  2. JYNT vs ADAG Comparison

JYNT vs ADAG Comparison

Compare JYNT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.92

Market Cap

138.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

SELL

Current Price

$2.96

Market Cap

146.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JYNT
ADAG
Founded
2010
2011
Country
United States
China
Employees
N/A
138
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
146.3M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JYNT
ADAG
Price
$8.92
$2.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.00
$8.00
AVG Volume (30 Days)
44.3K
108.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$117,696,356.00
N/A
Revenue This Year
$5.65
$3,688.61
Revenue Next Year
$3.86
$17.39
P/E Ratio
$76.42
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$1.33
52 Week High
$13.47
$3.53

Technical Indicators

Market Signals
Indicator
JYNT
ADAG
Relative Strength Index (RSI) 43.20 54.77
Support Level $8.25 $1.64
Resistance Level $10.47 $3.19
Average True Range (ATR) 0.40 0.30
MACD -0.01 -0.04
Stochastic Oscillator 44.80 48.01

Price Performance

Historical Comparison
JYNT
ADAG

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: